Clinical trial failure risk - CNS drug development has historically low success rates (~6-8% Phase 1 to approval vs ~12% industry average); failed trials can render company value near-zero overnight
Regulatory pathway uncertainty for precision psychiatry - FDA precedent for biomarker-driven patient selection in MDD/schizophrenia is limited, potentially requiring larger/longer trials than anticipated
Reimbursement challenges - payers increasingly scrutinize high-cost CNS drugs, particularly for conditions with generic alternatives; need to demonstrate significant clinical differentiation for favorable coverage
Platform validation risk - computational target identification approach unproven at scale; if lead programs fail, calls into question entire platform thesis
Large pharma re-entry into CNS - companies like Pfizer, Roche, and Lilly expanding psychiatry pipelines after years of underinvestment, bringing superior resources and commercial infrastructure
Novel mechanism competition - multiple biotechs pursuing psychedelic-based therapies (CMPS, MNMD), NMDA modulators, and other differentiated MOAs that could obsolete Neumora's approaches
Fast-follower risk - if Neumora validates a target, larger competitors can rapidly develop competing molecules with faster timelines to market
Cash runway pressure - $200M annual burn against ~$410M estimated cash (based on current ratio) implies need for financing by late 2026/early 2027, creating dilution risk or forcing suboptimal partnerships
Equity dilution from future financings - pre-revenue biotechs typically raise capital every 18-24 months; at $600M market cap, meaningful dilution likely in next round
No debt cushion - zero leverage means no access to non-dilutive debt financing if equity markets close; entirely dependent on equity capital markets
StructuralCompetitiveBalance Sheet
